AusperBio Announces $73 Million Series B Financing to Advance Clinical Development of AHB-137 and Expand Pipeline

Recently, AusperBio (Ausper Biopharma Co., Ltd. and AusperBio Therapeutics Inc.) announced the completion of a $73 million Series B financing round. This round was led by Shanghai Hankang Private Equity Fund Management Co., Ltd., with participation from Sherpa Healthcare Partners, CDH VGC, and a globally renowned industry investment institution. Additionally, previous investors Qiming Venture Partners, InnoPinnacle Fund, and YuanBio Venture Capital also contributed further investments.

The proceeds of this round of financing will be mainly used to advance the clinical trials of AHB-137, a core small nucleic acid innovative drug, in China and internationally, as well as the preparations for its early commercialization. In addition, the funds will also support the expansion of the company's new R&D pipeline and the continuous development and construction of the team.

AusperBio is a clinical-stage innovative drug development company operating simultaneously in China and the United States, committed to researching and developing First-in-class and Best-in-class self-innovative targeted delivery small nucleic acid drugs. AusperBio owns the proprietary intellectual property Med-Oligo™ ASO patent technology platform, focusing on functional cures for chronic hepatitis B (HBV) and highly efficient targeted treatments for liver diseases, while expanding into targeted small nucleic acid therapies for new targets beyond the liver. AusperBio's strategy is to combine its internationally leading Med-Oligo™ oligonucleotide technology with specific and highly efficient targeting technologies to address a wide range of currently unmet medical needs.